PharmaCyte Biotech, Inc.
Close on Oct 19, 2026
- Market cap
- $3.67M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2022 Ended Apr 30, 2022 | Jul 11, 2022 | After market close | – | – | – |
Press releases
Announcements PharmaCyte Biotech filed with the SEC
PRESS RELEASE DATED SEPTEMBER 2, 2025
Material agreement · Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE DATED AUGUST 18, 2025
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED MAY 21, 2024.
Material agreement · Acquisition or disposition completed · Other events · EX-99.1 to Form 8-K
marks expansion of corporate strategy to utilize significant cash position to create additional shareholder value
Material agreement · Other events · EX-99.1 to Form 8-K
Announces Cash Tender Offer for up to 7,750,000
Material agreement · Unregistered share sale · Charter or bylaw amendment · Shareholder vote results · Other events · EX-99.1 to Form 8-K
PharmaCyte Biotech to Implement Second $10-Million
Other events · EX-99.1 to Form 8-K
PharmaCyte Biotech Board of Directors Announces
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PharmaCyte Biotech Reaches Cooperation Agreement
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K